Indirect costs of respiratory syncytial virus hospitalizations: A commentary

Value in Health

Volumn 6, Issue 2, 2003, Pages 98-99

  Marks, Andrea S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY;

CHILD CARE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; INFECTION PREVENTION; INFECTION RISK; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRODUCTIVITY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

EID: 0037354437     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4733.2003.t01-1-00003.x     Document Type: Note

References (5)

1. Meissner HC, Welliver RC, Chartrand SA. Immunoprophylaxis with Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of syncytial virus infection in high risk infants: a consensus opinion. Pediatr Infect Dis J 1999;18:223-31.
2. American Academy of Pediatrics Committee on Infectious Diseases Prevention of RSV Infections. Indications for the use of Palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102: 1211-6.
3. Silverman W. A health care management company's experience with Palivizumab. Manag Care 2002;11: 45-6.
4. Leader S, Yang H, De Vincenzo J, et al. Time and out-of-pocket costs associated with RSV hospitalization of infants. Value Health 2003;6:100-106.
5. Lerner D, Amick BC 3rd, Rogers WH, et al. The Work Limitations Questionnaire. Med Care 2001; 39:72-85.